减肥药概念走高 礼来(LLY.US)涨超4%破历史新高

Group 1 - The core focus of the article is the rise in the stock prices of companies in the weight loss drug sector, particularly Eli Lilly, which reached a historic high [1] - Eli Lilly is reportedly close to finalizing a deal to acquire Ventyx Biosciences for over $1 billion, aimed at expanding its research pipeline in inflammatory bowel disease and neurodegenerative diseases [1] - UBS has maintained a buy rating on Eli Lilly's stock and raised the target price to $1,250 [1] Group 2 - Other companies in the weight loss drug sector, such as Amgen, Novo Nordisk, and Pfizer, also experienced stock price increases, with Amgen rising over 3% and Novo Nordisk and Pfizer both up over 1% [1]